Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects/events: clinically important movement disorder… compared with piperacetazine (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty).
1 finding from 1 review
Costs · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: clinically relevant response: · non response in schizophrenia
Antipsychotic dose increase showed no clear difference in global state: clinically relevant response: compared with antipsychotic dose continuation (low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes leaving the study early: tolerability ‐ leaving early due to adverse… compared with antipsychotic dose continuation (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
Antipsychotic dose increase showed no clear difference in leaving the study early: acceptability ‐ leaving early due to any… compared with antipsychotic dose continuation (low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · non response in schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes adverse effects ‐ at least one adverse effect compared with antipsychotic dose continuation (very low certainty).
1 finding from 1 review
Service use: time in hospital · non response in schizophrenia
1 finding from 1 review
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · non response in schizophrenia
1 finding from 1 review
Clinically significant response on global state · non response in schizophrenia
It is very uncertain whether increasing the antipsychotic dose changes global state: Clinically relevant response – as defined by trial… compared with switching the antipsychotic drug (very low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · non response in schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · non response in schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · non response in schizophrenia
1 finding from 1 review
Service use: 1. Average number of days in hospital per month ‐ by about 24 months · non response in schizophrenia
1 finding from 1 review
Average change in quality of life/satisfaction · non response in schizophrenia
1 finding from 1 review
Mental state: 2a. Negative symptoms ‐ No clinical important improvement ‐ negative symptoms (SANS) · schizophrenia
It is very uncertain whether mirtazapine adjunct changes mental state: specific negative symptoms ‐ clinically important… compared with placebo adjunct (very low certainty).
1 finding from 1 review
Mental state: clinically important change in mental state · schizophrenia
It is very uncertain whether mirtazapine adjunct changes mental state: overall mental state ‐ clinically important change* compared with placebo adjunct (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
1 finding from 1 review